The endocannabinoid system has emerged as a promising target for pharmacotherapy due to its involvement in various physiological functions and potential therapeutic applications in numerous diseases. The discovery of cannabinoid receptors and their endogenous lipid ligands has led to significant research on the endocannabinoid system's role in health and disease. Selective antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the enzyme fatty acid amidohydrolase, have facilitated studies on this system. The endocannabinoid system is implicated in a wide range of physiological functions, including those in the central and peripheral nervous systems and peripheral organs. Modulating this system has shown therapeutic promise in conditions such as mood and anxiety disorders, movement disorders, neuropathic pain, multiple sclerosis, spinal cord injury, cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity, and osteoporosis. The psychoactive properties of plant-derived or synthetic agonists have been a barrier to the development of cannabinoid medications. However, using CB1 receptor antagonists or enhancing endocannabinoid activity indirectly can avoid these issues. Selective CB2 receptor agonists, which lack psychoactive properties, may also be promising. The abuse potential of plant-derived cannabinoids can be limited through controlled compositions and careful dosing. The endocannabinoid system includes cannabinoid receptors CB1 and CB2, which are G protein-coupled receptors. CB1 is the most abundant in the mammalian brain, while CB2 is primarily expressed in immune and hematopoietic cells. Endocannabinoids such as anandamide and 2-AG are involved in various physiological processes, including appetite regulation, pain, and inflammation. Anandamide is a partial or full agonist of CB1 receptors, while 2-AG is generated from diacylglycerol by DAG lipase. Both endocannabinoids are degraded by fatty acid amide hydrolase (FAAH), which plays a key role in their in vivo degradation. The endocannabinoid system's role in appetite regulation is well-documented, with endocannabinoids influencing food intake through CB1 receptors. CB1 receptor-deficient mice show reduced food intake, indicating the involvement of endocannabinoids in appetite control. Leptin deficiency increases endocannabinoid activity, suggesting a regulatory role in appetite. The interaction between leptin and endocannabinoids occurs in the hypothalamus, where they modulate the mesolimbic dopaminergic pathway involved in food reward. Endocannabinoids also interact with other neurotransmitter systems, such as the opioid system, and may synergize in mediating the reinforcing effects of food. The endocannabinoid system's involvement in reward-seeking behavior and drug reward is also highlighted. The endocannabinoid system's role in appetite regulation is further supported by its interaction with neuropeptideThe endocannabinoid system has emerged as a promising target for pharmacotherapy due to its involvement in various physiological functions and potential therapeutic applications in numerous diseases. The discovery of cannabinoid receptors and their endogenous lipid ligands has led to significant research on the endocannabinoid system's role in health and disease. Selective antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the enzyme fatty acid amidohydrolase, have facilitated studies on this system. The endocannabinoid system is implicated in a wide range of physiological functions, including those in the central and peripheral nervous systems and peripheral organs. Modulating this system has shown therapeutic promise in conditions such as mood and anxiety disorders, movement disorders, neuropathic pain, multiple sclerosis, spinal cord injury, cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity, and osteoporosis. The psychoactive properties of plant-derived or synthetic agonists have been a barrier to the development of cannabinoid medications. However, using CB1 receptor antagonists or enhancing endocannabinoid activity indirectly can avoid these issues. Selective CB2 receptor agonists, which lack psychoactive properties, may also be promising. The abuse potential of plant-derived cannabinoids can be limited through controlled compositions and careful dosing. The endocannabinoid system includes cannabinoid receptors CB1 and CB2, which are G protein-coupled receptors. CB1 is the most abundant in the mammalian brain, while CB2 is primarily expressed in immune and hematopoietic cells. Endocannabinoids such as anandamide and 2-AG are involved in various physiological processes, including appetite regulation, pain, and inflammation. Anandamide is a partial or full agonist of CB1 receptors, while 2-AG is generated from diacylglycerol by DAG lipase. Both endocannabinoids are degraded by fatty acid amide hydrolase (FAAH), which plays a key role in their in vivo degradation. The endocannabinoid system's role in appetite regulation is well-documented, with endocannabinoids influencing food intake through CB1 receptors. CB1 receptor-deficient mice show reduced food intake, indicating the involvement of endocannabinoids in appetite control. Leptin deficiency increases endocannabinoid activity, suggesting a regulatory role in appetite. The interaction between leptin and endocannabinoids occurs in the hypothalamus, where they modulate the mesolimbic dopaminergic pathway involved in food reward. Endocannabinoids also interact with other neurotransmitter systems, such as the opioid system, and may synergize in mediating the reinforcing effects of food. The endocannabinoid system's involvement in reward-seeking behavior and drug reward is also highlighted. The endocannabinoid system's role in appetite regulation is further supported by its interaction with neuropeptide